Academic literature on the topic 'Altiazem'

Objectives: To study the time-dependent hemodynamic affects of altiazem PP-180 and the blood circulation parameters in patients with arterial hypertension of the II degree in outpatient polyclinic conditions. Methods: The study included 78 patients with essential II grade AH aged 42 to 73 years (mean age of 57.65 ± 0.6). Among them were 28 men and 50 women. The duration of the disease ranged from 4 to 23 years (an average of 9.2 ± 0.12). All the groups involved in the research were divided into two subgroups: the main group and the control group. The control gr oup included 30 patients, who took A-180 once a day at non-fixed hours. The main group included 48 patients, who were divided into random subgroups depending on the time they took A-180 once a day. Within 3 days prior to treatment and during the 10-day treatment course, the medical staff measured all the pateints' heart rate and blood pressure by NC Korotkoff every 3 hours, 6 times a day. The patients' heart rate and blood pressure were alternatively s elfmeasured. Prior to treatment and at the end of the 10-day course of therapy with altiazem PP-180, all the patients involved in the research underwent ECG examination and echocardiography on the Aloka machine (Japan). Findings: When taken at different hours of the day - both fixed and non-fixed hours - altiazem PP-180 caused a distinct hypotensive effect in patients with the II degree AH in outpatient polyclinic conditions. The most favorable hemodynamic support for the hypotensive effect of altiazem PP-180 was observed when patients took it at 7 a.m., 10 a.m. and 10 p.m. in their normal mode of work and rest. When patients took altiazem PP-180 at 1 p.m, 4 p.m. and 7 p.m., its hypotensive effect was due to less favorable hemodynamic support. Keywords: arterial hypertension; altiazem; hemodynamic parameters; outpatient conditions.

Background: The objective is to study the time-dependent hemodynamic effects of altiazem PP-180 and the blood circulation parameters in patients with arterial hypertension of the II degree in outpatient polyclinic conditions.Methods: The study included 78 patients with essential II grade AH aged 42 to 73 years (mean age of 57.65 ± 0.6). Among them were 28 men and 50 women. The duration of the disease ranged from 4 to 23 years (an average of 9.2 ± 0.12). All the groups involved in the research were divided into two subgroups: the main group and the control group. The control group included 30 patients, who took A-180 once a day at non-fixed hours. The main group included 48 patients, who were divided into random subgroups depending on the time they took A-180 once a day. Within 3 days prior to treatment and during the 10-day treatment course, the medical staff measured all the pateints’ heart rate and blood pressure by NC Korotkoff every 3 hours, 6 times a day. The patients’ heart rate and blood pressure were alternatively self-measured. Prior to treatment and at the end of the 10-day course of therapy with altiazem PP-180, all the patients involved in the research underwent ECG examination and echocardiography on the Aloka machine (Japan).Results: The most favorable hemodynamic support for the hypotensive effect of altiazem PP-180 was observed when patients took it at 7 a.m., 10 a.m. and 10 p.m. in their normal mode of work and rest. When patients took altiazem PP-180 at 1 p.m, 4 p.m. and 7 p.m., its hypotensive effect was due to less favorable hemodynamic support.Conclusions: When taken at different hours of the day - both fixed and non-fixed hours - altiazem PP-180 caused a distinct hypotensive effect in patients with the II degree AH in outpatient polyclinic conditions.Bangladesh Journal of Medical Science Vol.17(3) 2018 p.360-368

Althiazem РР is a selective blocker of slow calcium channels belonging to long-acting benzodiazepines, used for treating arterial hypertension. The efficacy and tolerance of 3-month monotherapy with althiazem PP in a daily dose of 180-360 mg was studied in 20 patients with non-insulin-dependent diabetes mellitus (NIDDM) combined with mild and moderate arterial hypertension. Acute drug test with daily arterial pressure (AP) monitoring showed that the number of the drug doses was determined by the severity of arterial hypertension and the circadian rhythm (r^0.68 and r—0.83, respectively). Daily monitoring of AP showed a significant decrease in the mean 24-h, mean daily, and mean nightly AP values. Diastolic AP normalized in 75%opatients and decreased by 10 mm Hg and more in 25%. "Pressure loading” in the daytime and at night decreased by 29.1 and 31.3%o, respectively. Increased variability of systolic AP for 24-h period decreased by 12.5%) during awakening hours and by 9.8% during sleeping. Heart rate virtually did not change. The drug exerted no negative effects on normal biphasic AP rhythm. Althiazem PP decreased the morning APpeak without notably changing the extent and rate of AP rises during the early morning hours. The drug had no negative effects on carbohydrate and lipid metabolism. Althiazem PP therapy had to be discontinued in only one female patient because of strong headaches. These data confirm high efficacy and good tolerance of althiazem PP as monotherapy for arterial hypertension in patients with NIDDM.

The article is devoted to investigation the comparative efficacy of therapy with drugs of calcium antagonists with prolong action — dilren and altiasem PP in old patients, suffering from ischemic heart disease, stable stenocardia 2–3 functional class. There were established more efficacy of therapy with dilren then altiasem PP in the relation to clinical symptoms, hemodynamical parameters and their circadian chronostructure. These data manifested by more essential antianginal, antiischemic and vasodilated effects of dilren then of altiasem PP. There were more essential the increase of tolerance to physical loading, promotion of pumping myocardial function under the influence of dilren and tendency to normalization in circadian organization of hemodynamic parameters.

Aim: To investigate interpolymer complexes (IPCs) formation between carbopol and cationic polymers such as chitosan and Eudragit E for oral controlled drug delivery systems. Methodology: The prepared IPCs were investigated using Fourier transform infra-red spectroscopy (FT-IR) and differential scanning calorimetry (DSC). Chitosan-carbopol and Eudragit E-carbopol IPCs loaded with diltiazem hydrochloride (DTZ HCl) with different drug:polymer ratios were also prepared. Diltiazem hydrochloride tablets were prepared using polymers alone, physical mixtures of chitosan or Eudragit E with carbopol and the corresponding drug loaded IPCs. In-vitro release studies were carried out in two dissolution media; 0.1 NHCl of pH 1.2 and phosphate buffer of pH 7.4. Results: The dissolution rate of DTZ HCl from the prepared tablets were found to be dependant on the interaction between chitosan or Eudragit E with carbopol in the physical mixture, drug:polymer ratio and pH of the dissolution medium. Tablets prepared using chitosan – carbopol IPC, Eudragit E – carbopol IPC, and Eudragit E – carbopol physical mixture of drug:polymer ratio 1:5 were selected for the in-vivo study using rabbits. The results showed a lower peak plasma concentration and marked prolonged release effect of tablets containing Eudragit E – carbopol IPC and the corresponding physical mixture compared to that of commercial Altiazem tablets. Conclusion: Tablets containing Eudragit E – carbopol or chitosan – carbopol physical mixtures showed prolonged drug release compared to that containing the corresponding IPCs, Furthermore, Eudragit E- carbopol matrix tablets showed slower drug release than that of chitosan – carbopol.